Published • loading... • Updated
Valerio Therapeutics and Etherna Immunotherapies Are Progressing Towards Finalizing the Documentation Related to the Proposed Acquisition.
Summary by Business Wire
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
VILLEJUIF, France--(BUSINESS WIRE)--Regulatory News: Valerio Therapeutics (FR0010095596 - ALVIO), a clinical-stage biotechnology company pioneering next-generation precision therapies (“Valerio” or the “Company”), provides an update on its proposed acquisition of 100% of the share capital of Etherna Immunotherapies NV (“Etherna”) (the “Acquisition”). On July 1, 2026, Valerio announced that it had submitted a firm offer for the Acquisition based …
·Crystal River, United States
Read Full ArticleCoverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
